CME-in-the-Letter, Goals & Objectives

Accreditation:

Therapeutic Research Center designates this activity for 1 contact hour.

CME Accreditation:

Therapeutic Research Center designates this enduring, journal-based CME activity for a maximum of 12 AMA PRA Category 1 Credits™. Each monthly issue is 1 credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Accreditation:

Therapeutic Research Center designates this activity for 1 contact hour.

AAFP:

This Enduring Material activity, Prescriber's Letter CME-in-the-Letter, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Approved for 1.0 AAFP Prescribed credits. Term of approval begins 05/01/2018. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AOA:

Prescriber's Letter is eligible for AOA Category 2-B credit. Each monthly issue is 1 hour. Each physician should claim only those hours of credit that s/he actually spent in the educational activity.

ACEP:

Approved by the American College of Emergency Physicians for a maximum of 12.00 hour(s) of ACEP Category I credit. Each monthly issue is 1 credit.

Physician Assistants::

AAPA and NCCPA accept AMA PRA Category 1 Credits™ from organizations accredited by ACCME. Therapeutic Research Center is accredited by ACCME. NCCPA accepts AAFP Prescribed credits for recertification.


Physicians in Canada:

Members of The College of Family Physicians of Canada are eligible to receive Mainpro®-M2 credits (equivalent to AAFP Prescribed credits) due to a reciprocal agreement with the American Academy of Family Physicians. Therapeutic Research Center CME activities are eligible for either Section 2 or Section 4 (when creating a personal learning project) in the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada (RCPSC).

Target Readers / Needs Assessment:

This activity is intended for physicians and other healthcare team members. These clinicians have expressed their need to learn about new developments in drug therapy by subscribing to TRC.

CME Objectives:

After reading Prescriber's Letter, participants will be able to identify emerging trends in drug therapy; evaluate the role of new drugs and new indications in the continuum of care; summarize new therapeutic guidelines; recognize new contraindications and interactions; and promote patient safety through appropriate selection and monitoring of drug therapy.

Participation / Time To Complete:

Credit will be awarded to participants who answer at least 70% of the quiz questions correctly online. After successful completion of this course, the statement of participation/course completion may be printed online. The estimated time needed to read and reflect on each issue of Prescriber's Letter and complete the post-test is one hour. Credit may be claimed for one year from the date of each issue.

Disclosure:

The editors of this activity and its publisher, Therapeutic Research Center (TRC), have no relevant financial interests related to the products or services covered by this activity. TRC does not receive any commercial support and does not accept any advertising. It is completely independent and is supported entirely by subscriptions. TRC focuses on delivering completely objective, unbiased drug information and advice for the benefit of subscribers. Our editors have thoroughly researched the information with input from experts, government agencies, and national organizations. Users of this document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical or legal judgments. Information and Internet links in this article were current as of the date of publication.

Software / Hardware Requirements (Test your system here):

• Operating System: Windows 10, Windows 8.1+ Pro, Windows 7, Android 4.4+, Apple Mac OS X 10.10+, Apple iOS 9+
• Internet Browser: Google™ Chrome™ 55+, Internet Explorer^® 11.0+, Firefox^® 51+, Safari™ 9+ (Mac and iOS devices only), Edge Browser
• Hardware: Sound Card with speakers or headphones, Screen with 1024x768+ resolution support
• Processor: 1.6GHz or better (Dual core processors preferred)
• RAM: 2 GB or higher
• Internet Connection: Dedicated high speed connection of 900kbps+

Your Privacy

In order to provide you with continuing education, Therapeutic Research Center (TRC) obtains information such as your name, address, email address, phone number, payment information, etc. We treat this information as confidential and use it to provide you with the best service possible. TRC has NEVER released any of this information to any outside organization for such organization's own commercial or marketing use and has a policy against doing so. We do not engage in renting out, selling, or trading names of subscribers or any information about any subscriber.

To provide you with valuable services, we will occasionally employ third parties to meet your needs. In such cases, only the information needed to meet your need will be shared with the outside organization. TRC only employs third parties that have similarly protective privacy policies. We do not allow any other organization to send you unsolicited emails about any products or services. We might send you information about your subscription, your continuing education credits, or our own drug information services. We do not gather data or track your web usage of any websites other than our own. We invite you to ask us about any privacy concern you may have by calling us or emailing privacyofficer@pletter.com.

Therapeutic Research Center
Tel:(209) 472-2240 Fax:(209) 472-2249
Copyright^© 1995-2017, All rights reserved.